Frontiers in Cardiovascular Medicine (Jun 2023)

Inflammation as a therapeutic target in heart failure with preserved ejection fraction

  • Zhen Hui Peh,
  • Adel Dihoum,
  • Dana Hutton,
  • J. Simon C. Arthur,
  • Graham Rena,
  • Faisel Khan,
  • Chim C. Lang,
  • Ify R. Mordi

DOI
https://doi.org/10.3389/fcvm.2023.1125687
Journal volume & issue
Vol. 10

Abstract

Read online

Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a significant unmet need for new strategies to improve clinical outcomes in HFpEF patients. Inflammation is widely thought to play a key role in HFpEF pathophysiology and may represent a viable treatment target. In this review focusing predominantly on clinical studies, we will summarise the role of inflammation in HFpEF and discuss potential therapeutic strategies targeting inflammation.

Keywords